Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Keyphrases

• Glucagon Secretion 100%
• Therapeutic Effect 100%
• Current Therapies 100%
• Glucagon 71%
• Type 2 Diabetes Mellitus (T2DM) 28%
• Safety Profile 28%
• Efficacy Profile 28%
• Pathophysiology 14%
• A1 Receptor 14%
• Hyperglycemia 14%
• Insulin 14%
• Antidiabetic Drugs 14%
• Metformin 14%
• Receptor Agonist 14%
• Glucagon-like 14%
• Glucose-lowering Drugs 14%
• Drug Efficacy 14%
• Hyperglucagonemia 14%
• Dipeptidyl peptidase-4 (DPP-4) 14%
• Hypoglycemia Risk 14%
• Antidiabetic Agents 14%
• Drug Safety 14%
• Drug Influence 14%
• Sulfonylurea Compounds 14%
• Targeted Drugs 14%
• Diabetologist 14%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 14%
• Personal Effectiveness 14%
• Amylin Mimetics 14%

Medicine and Dentistry

• Glucagon Release 100%
• Therapy Effect 100%
• Glucagon 71%
• Maturity Onset Diabetes of the Young 28%
• Antidiabetic Agent 28%
• Pathophysiology 14%
• Hypoglycemia 14%
• Glycon 14%
• Glucagon-Like Peptide-1 Agonist 14%
• Hyperglycemia 14%
• Hyperglucagonemia 14%
• Dipeptidyl Peptidase-4 Inhibitor 14%
• Drug Delivery System 14%
• Drug Efficacy 14%
• Amylin 14%
• Sodium Glucose Cotransporter 2 Inhibitor 14%
• Sulfonylurea Derivative 14%

Biochemistry, Genetics and Molecular Biology

• Glucagon Release 100%
• Glucagon 71%
• Hyperglycemia 14%
• Cotransporter 14%
• Glucagon-Like Peptide 1 Receptor 14%
• Receptor Agonists 14%
• Sulfonylurea 14%
• Dipeptidyl Peptidase-4 14%
• Drug Targeting 14%
• Amylin 14%
• Drug Efficacy 14%
• Drug Safety 14%